Ravulizumab · Ultomiris
Monoclonal antibody
Evidence outlook
Approved: Myasthenia Gravis, Thrombotic Microangiopathy, Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, IgA Nephropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (4)
- the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
- Paroxysmal Nocturnal Hemoglobinuria (PNH) ULTOMIRIS® (ravulizumab for injection) is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). Atypical Hemolytic Uremic Syndrome (aHUS) ULTOMIRIS® (ravulizumab for injection) is indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy (TMA). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin...
- Paroxysmal nocturnal haemoglobinuria (PNH) in adults (initial EU authorisation)
- Treatment of paroxysmal nocturnal hemoglobinuria
Development in Chronic Kidney Disease stopped (2026-04) after a negative readout. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03920293 NCT03920293 · Myasthenia Gravis Registry: NCT03920293 | 3 | Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26 (Baseline, Week 26) 2021-05-11 | Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26 (Baseline, Week 26): Ravulizumab -3.1 units on a scale (Standard Error 0.38) | Placebo -1.4 units on a scale (Standard Error 0.37) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
Other Complement C5 drugs
Avacincaptad pegol, Eculizumab, Cemdisiran, Gefurulimab, Pozelimab and 1 more. Compare all 7 Complement C5 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Generalized Myasthenia Gravis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ravulizumab (Ultomiris): this drug | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Avacincaptad Pegol (Izervay) | Approved(overall) | RNA Aptamer | Complement C5 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed | |
| Efgartigimod Alfa (Vyvgart) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved | Monoclonal antibody | CD19 | Reliable signal | NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4) | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Gefurulimab (Klygefa) | Phase 3 | Antibody-derived scaffold | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Phase 3 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-6628 | Phase 1/2(overall) | Antibody fragment | Complement C5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ultomiris (Ravulizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (5)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (2)
November 2027 (1)
What to watch
2028 (3)
September 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2030 (1)
January 2030 (1)
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent